Fig. 4From: Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysisEffects of GLP1R agonists on myocardial infarction, stroke, hospitalization for heart failure, and MACE. CI, confidence interval; GLP1R, glucagon-like peptide–1 receptor; HR, hazard ratio; MACE: major adverse cardiovascular eventBack to article page